Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8811887 | 0.90 | ACE2 (0.35) | ACE2LMNA | |
| SCHEMBL294759 | 0.90 | ACE2 (0.35) | ACE2LMNA | |
| SCHEMBL2431181 | 0.90 | ACE2 (0.35) | ACE2LMNA | |
| SCHEMBL15326983 | 0.90 | ACE2 (0.35) | ACE2LMNA | |
| SCHEMBL15326957 | 0.90 | ACE2 (0.35) | ACE2LMNA | |
| SCHEMBL15873757 | 0.90 | ACE2 (0.35) | ACE2LMNA | |
| SCHEMBL4575538 | 0.90 | ACE2 (0.35) | ACE2LMNA | |
| SCHEMBL4979534 | 0.90 | ACE2 (0.35) | ACE2LMNA | |
| SCHEMBL1410664 | 0.90 | ACE2 (0.35) | ACE2LMNA | |
| SCHEMBL384479 | 0.90 | ACE2 (0.35) | ACE2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022033-B2 | Echinocandin/carbohydrate complexes | ELI LILLY AND COMPANY (US) | 2011-09-20 | — | — | US | claimed |
| US-20090258820-A1 | ECHINOCANDIN/CARBOHYDRATE COMPLEXES | ELI LILLY AND COMPANY | 2009-10-15 | — | — | US | claimed |
| US-7550428-B2 | Echinocandin/carbohydrate complexes | ELI LILLY AND COMPANY (US) | 2009-06-23 | — | — | US | claimed |
| EP-1204677-B1 | CYCLOHEXAPEPTIDE COMPOUNDS, PROCESS FOR THEIR PRODUCTION AND THEIR USE AS A PHARMACEUTICAL | AVENTIS PHARMA GMBH (DE) | 2008-12-03 | — | — | EP | claimed |
| US-7166572-B1 | Cyclohexapeptide compounds, processes for their production and their use as a pharmaceutical | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2007-01-23 | — | — | US | claimed |
| EP-1073675-B1 | A PROCESS FOR THE CONVERSION OF ECHINOCANDIN CLASS OF PEPTIDES TO THEIR C4-HOMOTYROSINE MONODEOXY ANALOGUES | AVENTIS PHARMA GMBH (DE) | 2007-01-03 | — | — | EP | claimed |
| US-20060111277-A1 | treating fungal infections; improved thermal stability and water solubility; releasing carbohydrate upon dispersion of the complex in water | ELI LILLY AND COMPANY | 2006-05-25 | — | — | US | claimed |
| US-7041637-B2 | Echinocandin/carbohydrate complexes | ELI LILLY AND COMPANY (US) | 2006-05-09 | — | — | US | claimed |
| EP-1582204-A2 | Echinocandin pharmaceutical formulations containing micelle-forming surfactants | Eli Lilly & Company (US) | 2005-10-05 | — | — | EP | claimed |
| EP-1156782-B1 | ECHINOCANDIN PHARMACEUTICAL FORMULATIONS CONTAINING MICELLE-FORMING SURFACTANTS | LILLY CO ELI (US) | 2005-05-04 | — | — | EP | claimed |
| EP-1156784-A1 | PROCESSES FOR MAKING PHARMACEUTICAL ORAL ECB FORMULATIONS AND COMPOSITIONS | ELI LILLY AND COMPANY (US) | 2001-11-28 | — | — | EP | claimed |
| EP-1157030-A1 | ECHINOCANDIN/CARBOHYDRATE COMPLEXES | ELI LILLY AND COMPANY (US) | 2001-11-28 | — | — | EP | claimed |
| EP-1156782-A1 | ECHINOCANDIN PHARMACEUTICAL FORMULATIONS CONTAINING MICELLE-FORMING SURFACTANTS | ELI LILLY AND COMPANY (US) | 2001-11-28 | — | — | EP | claimed |
| EP-1073675-A1 | A PROCESS FOR THE CONVERSION OF ECHINOCANDIN CLASS OF PEPTIDES TO THEIR C4-HOMOTYROSINE MONODEOXY ANALOGUES | Aventis Pharma Deutschland GmbH (DE) | 2001-02-07 | — | — | EP | claimed |
| WO-2001007468-A2 | NOVEL CYCLOHEXAPEPTIDE COMPOUNDS, PROCESSES FOR THEIR PRODUCTION AND THEIR USE AS A PHARMACEUTICAL | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-02-01 | — | — | WO | claimed |
| WO-2000052037-A1 | ECHINOCANDIN/CARBOHYDRATE COMPLEXES | ELI LILLY AND COMPANY (US) | 2000-09-08 | — | — | WO | claimed |
| WO-2000051567-A1 | PROCESSES FOR MAKING PHARMACEUTICAL ORAL ECB FORMULATIONS AND COMPOSITIONS | ELI LILLY AND COMPANY (US) | 2000-09-08 | — | — | WO | claimed |
| WO-2000051564-A1 | ECHINOCANDIN PHARMACEUTICAL FORMULATIONS CONTAINING MICELLE-FORMING SURFACTANTS | ELI LILLY AND COMPANY (US) | 2000-09-08 | — | — | WO | claimed |
| US-6110933-A | AN ENZYME INHIBITOR TREATING PANCREATITIS, HEPATITIS, CHRONIC RENAL FAILURE, ENDOTOXIN SHOCK, GRAM-NEGATIVE SEPTIC SHOCK, ARTHRITIS, RESPIRATORY DISEASE, HEART DISEASE, ALLERGIC DISEASE, THROMBOSIS, ARTERIOSCLEROSIS, PAIN | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-08-29 | — | — | US | claimed |
| WO-1999055727-A1 | A PROCESS FOR THE CONVERSION OF ECHINOCANDIN CLASS OF PEPTIDES TO THEIR C4-HOMOTYROSINE MONODEOXY ANALOGUES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 1999-11-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111277-A1 | treating fungal infections; improved thermal stability and water solubility; releasing carbohydrate upon dispersion of the complex in water | ERG28, TREH, MAN2A1 | ACE2 3243/4885LMNA 1607/4885 |
| US-20090258820-A1 | ECHINOCANDIN/CARBOHYDRATE COMPLEXES | ERG28, TREH, MAN2A1 | ACE2 3465/4885LMNA 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.